This article was originally published in The Gray Sheet
Cell therapy company completes a $63 mil. private placement with institutional investors. Irvine, California-based Nexell will use the proceeds to retire about $34 mil. in convertible subordinated debentures held by shareholder Baxter, as well as for "general corporate purposes." Nexell's Isolex 300i gained FDA approval in July for the selection of hematopoietic stem cells and the removal of tumor cells from autologous peripheral blood grafts used to restore cancer patients' immune and blood-forming systems following high dose chemotherapy (1"The Gray Sheet" July 12, p. 11). Lehman Brothers served as placement agent for the transaction
You may also be interested in...
Nexell Therapeutics plans to file two premarket approval applications in the second half of 2001 to expand labeling for its Isolex 300i magnetic cell selection system, which gained FDA approval July 6.
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies